Allspring Global Investments Holdings LLC lowered its holdings in Stryker Co. (NYSE:SYK – Free Report) by 12.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,664 shares of the medical technology company’s stock after selling 13,567 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Stryker were worth $32,209,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. St. Johns Investment Management Company LLC grew its position in Stryker by 2.1% during the second quarter. St. Johns Investment Management Company LLC now owns 5,129 shares of the medical technology company’s stock valued at $1,745,000 after buying an additional 107 shares during the period. SlateStone Wealth LLC acquired a new stake in Stryker during the second quarter valued at $684,000. Bailard Inc. grew its position in Stryker by 127.5% during the second quarter. Bailard Inc. now owns 25,264 shares of the medical technology company’s stock valued at $8,596,000 after buying an additional 14,157 shares during the period. Verdence Capital Advisors LLC grew its position in Stryker by 20.6% during the second quarter. Verdence Capital Advisors LLC now owns 1,353 shares of the medical technology company’s stock valued at $460,000 after buying an additional 231 shares during the period. Finally, Catalyst Financial Partners LLC grew its position in Stryker by 5.3% during the second quarter. Catalyst Financial Partners LLC now owns 1,402 shares of the medical technology company’s stock valued at $477,000 after buying an additional 70 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.
Insider Buying and Selling
In related news, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the transaction, the chief financial officer now owns 2,852 shares in the company, valued at $949,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the sale, the chief financial officer now owns 2,852 shares in the company, valued at approximately $949,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Viju Menon sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The disclosure for this sale can be found here. Insiders sold 210,600 shares of company stock worth $68,330,400 over the last 90 days. 5.90% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on SYK
Stryker Price Performance
Shares of SYK opened at $358.51 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. The stock has a market cap of $136.62 billion, a PE ratio of 40.93, a P/E/G ratio of 2.74 and a beta of 0.89. The firm has a 50-day simple moving average of $336.10 and a two-hundred day simple moving average of $341.09. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The firm had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.54 earnings per share. As a group, analysts forecast that Stryker Co. will post 12 EPS for the current year.
Stryker Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio is currently 36.53%.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Stories
- Five stocks we like better than Stryker
- Airline Stocks – Top Airline Stocks to Buy Now
- Snowflake’s Risk/Reward Profile Is Too Good To Miss
- Using the MarketBeat Dividend Yield Calculator
- Akamai: AI Tailwinds Drive Edge Computing and Security Growth
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- DoorDash Stock Sprints Higher on EPS Beat and Raised Guidance
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.